Challenges in the Management of Long-Therm Corticotherapy Treatment at Smoker Pacient with Severe Asthma

Asthma is a chronic obstructive disease with high morbidity and mortality despite modern diagnostic and treatment methods. Oral corticosteroid therapy has been the mainstay treatment for severe asthma for almost a century, improving the patient's quality of life by reducing the severity and frequency of asthma attacks. However, long-term systemic corticosteroid administration has disadvantages owing to the increased prevalence of adverse effects. In recent years, the use of targeted biological therapies has increased, prompting us to question the current role of corticosteroid therapy in the management of severe eosinophilic asthma. We present the case of a 49-year-old female patient, who smoked (25 pack-years) and was diagnosed with asthma 20 years ago based on clinical, biological, and spirometric criteria. The patient was treated with prednisone (10 mg/day). This study aimed to demonstrate the potential long-term effects of corticosteroid administration in smokers with severe asthma who had clear criteria for initiating biological therapy.